Xencor, Inc. $XNCR Shares Purchased by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. boosted its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 189.0% in the third quarter, Holdings Channel.com reports. The firm owned 2,082,243 shares of the biopharmaceutical company’s stock after acquiring an additional 1,361,803 shares during the period. Jefferies Financial Group Inc.’s holdings in Xencor were worth $51,952,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of XNCR. BlackRock Inc. bought a new stake in shares of Xencor in the second quarter valued at about $219,785,000. Primecap Management Co. CA bought a new position in shares of Xencor during the second quarter worth about $163,919,000. Dimensional Fund Advisors LP grew its holdings in shares of Xencor by 3.6% during the first quarter. Dimensional Fund Advisors LP now owns 1,294,887 shares of the biopharmaceutical company’s stock worth $15,613,000 after buying an additional 45,599 shares in the last quarter. Legal & General Group Plc acquired a new stake in Xencor in the 2nd quarter valued at approximately $17,568,000. Finally, Johnson & Johnson acquired a new stake in Xencor in the 2nd quarter valued at approximately $12,043,798.

Analyst Upgrades and Downgrades

Several research firms have commented on XNCR. Wells Fargo & Company boosted their target price on Xencor from $30.00 to $44.00 and gave the company an “overweight” rating in a research note on Tuesday, October 27th. Wedbush raised their price target on shares of Xencor from $30.00 to $45.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 27th. Cantor Fitzgerald started coverage on shares of Xencor in a research note on Thursday, November 5th. They set an “overweight” rating and a $70.00 price target for the company. Truist Financial lifted their price objective on shares of Xencor from $29.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, October 27th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Xencor from $14.00 to $21.00 and gave the stock a “neutral” rating in a research report on Thursday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $42.22.

Xencor Stock Performance

Shares of NASDAQ XNCR opened at $39.97 on Thursday. The business has a 50-day moving average of $26.91 and a 200-day moving average of $17.85. Xencor, Inc. has a fifty-two week low of $10.38 and a fifty-two week high of $40.60.

Xencor (NASDAQ:XNCR) last released its earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.83. Xencor had a negative return on equity of 21.28% and a negative net margin of 58.79%. The business had revenue of $116.52 million for the quarter, compared to analyst estimates of $63.00 million. During the same quarter in the prior year, the company posted ($0.08) earnings per share. Xencor’s revenue was up 453.3% on a year-over-year basis. Research analysts anticipate that Xencor, Inc. will post -2.61 EPS for the current fiscal year.

Xencor Profile

Xencor, Inc. is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases. The company’s XmAb technology platform modifies antibody structures to create treatments with properties such as enhanced immune-cell activity or the ability to bind to more than one target. Xencor advances its own drug candidates and works with other biopharmaceutical companies through research collaborations and licensing agreements. Its development programs include antibody-based approaches designed to engage immune cells or block disease-related targets.